Search Medical Condition
Please enter condition
Please choose location from dropdown

Molluscum Contagiosum Clinical Trials

A listing of Molluscum Contagiosum medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (5) clinical trials

Now enrolling patients ages 2 years and older with Molluscum Contagiosum.

Phase N/A

A Dose Range-Finding Phase 2 Trial of a Botanical Drug for the Treatment of Molluscum Contagiosum in Pediatric Subjects

This trial will be a single-center, double-blind, randomized, placebo-controlled safety and efficacy trial to evaluate the efficacy and safety of VIR003 treatment regimen when administered to pediatric subjects with molluscum contagiosum. Once subject eligibility is confirmed the subject will start the Treatment Period of the study. All subjects will receive ...


Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

This is a Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) cantharidin] in subjects 2 years and older with Molluscum Contagiosum. Up to 40 subjects will be enrolled in the study with the goal of 16 meeting criteria ...


Cantharidin Application in Molluscum Patients-1

This is a Phase 3, multi-center, randomized, double-blind, placebo (vehicle)-controlled, pivotal study that will be conducted in the United States to determine the efficacy and safety of VP-102 following treatment of molluscum lesions for up to 4 treatments, every 21 days, with VP-102/placebo in 250 subjects. Subjects will receive active ...


A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in up to approximately 192 or 256 non-immunocompromised subjects with molluscum contagiosum. Subjects who satisfy entry criteria will be randomized 3:1 to ascending, sequential dose cohorts of SB206. The highest tolerated dose will also be ...